mRNA 1403
Alternative Names: mRNA-1403Latest Information Update: 17 Oct 2024
Price :
$50 *
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Norovirus infections
Most Recent Events
- 24 Sep 2024 Phase-III clinical trials in Norovirus infections (Prevention) in USA (IM) (NCT06592794)
- 19 Sep 2024 ModernaTX plans a phase III trial for Norovirus infections (Prevention) in Canada, Puerto Rico and USA (IM, Injection) (NCT06592794)
- 27 Mar 2024 Moderna Therapeutics plans a pivotal phase-III trial for Norovirus infections